Deciphera Pharmaceuticals Inc Stock News

Deciphera (DCPH) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock down is after-hours trading.

Deciphera (DCPH) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock down is after-hours trading.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Humanigen Announces Agreement With French CDMO For Fill And Finish Services For Lenzilumab Humanigen,

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Q4 2021 Earnings Conference Call February 08, 2022, 04:30 PM ET Company Participants Maghan Meyers - SVP, Argot Partners Steve Hoerter -

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -1.34% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for

Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steve Hoerter on Q4 2021 Results - Earnings Call Transcript

Deciphera Pharmaceuticals press release (DCPH): Q4 GAAP EPS of -$1.51 misses by $0.03.Revenue of $24.2M (+24.2% Y/Y) beats by $0.92M.

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the fourth quarter and year ended December 31, 2021, and provided a corporate update. “I am immensely proud of our organization’s achievements in 2021 and believe that we are well positioned for long-term success as we work towards our expected milestones in 2022,” said Steve Hoerter, President and Chief Executive Officer of Deciphera Pharmaceuticals. “While the unexpected result

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -1.34% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Axsome To Pay $312,500 To Settle Patent Infringement Litigation With Baudax Axsome Therapeutics, Inc.

Deciphera Pharmaceuticals (NASDAQ:DCPH) is scheduled to announce Q4 earnings results on Tuesday, February 8th, after market close.The consensus EPS Estimate is -$1.40 and the

Let us take a look at three biotech/drug companies that are slated to release quarterly results on Feb 8.

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some bi

Deciphera Pharmaceuticals, Inc. (DCPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Deciphera Pharmaceuticals, Inc. (DCPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.